Five-Year Outcomes After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease
The Final Analysis of the Arterial Revascularization Therapies Study (ARTS) Randomized Trial
Patrick W. Serruys, MD, PhD, FACC*,*,
Andrew T.L. Ong, MBBS, FRACP*,
Lex A. van Herwerden, MD, PhD*,
J. Eduardo Sousa, MD, PhD, FACC ,
Adib Jatene, MD ,
Johannes J.R.M. Bonnier, MD, PhD ,
Jacques P.M.A. Schönberger, MD, PhD ,
Nigel Buller, MBBS, FRCP||,
Robert Bonser, MBChB, FRCP, FRCS||,
Clemens Disco, MSc¶,
Bianca Backx, PhD¶,
Paul G. Hugenholtz, MD, FACC¶,
Brian G. Firth, MD, PhD, FACC# and
Felix Unger, MD, FACC**
* Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Hospital do Coracao, Sao Paulo, Brazil
Catharina Ziekenhuis, Eindhoven, the Netherlands
|| The Queen Elisabeth Hospital, Birmingham, United Kingdom
¶ Cardialysis, Rotterdam, the Netherlands
# Cordis, a Johnson & Johnson company, Warren, New Jersey
** the University Klinik für Herzchirurgie, Salzburg, Austria

View larger version (27K):
[in a new window]
|
Figure 1 Flow chart. CABG = coronary artery bypass grafting.
|
|

View larger version (23K):
[in a new window]
|
Figure 2 (A) Kaplan-Meier curves showing freedom from death. (B) Kaplan-Meier curves showing freedom from death/cerebrovascular accident/myocardial infarction or revascularization. (C) Kaplan-Meier curves showing freedom from death/cerebrovascular accident/myocardial infarction or revascularization. (D) Kaplan-Meier curves showing freedom from revascularization. CABG = coronary artery bypass grafting.
|
|
|